Target Synonym: DRIL;BDP;DRIL2;ARID3B
Background: ARID3B, a member of the AT-rich interaction domain (ARID) family of proteins, plays an essential role in the survival of neural crest during embryogenesis. ARID3B seems to play a key role in the malignant transformation of neuroblastoma and may serve not only as a marker of malignancy but also as a potential target for cancer therapy of stage IV neuroblastoma for which there is currently no effective treatment available. ARID3B is a DNA binding protein that is overexpressed in neuroblastoma and ovarian cancer. ARID3B has different patterns in normal tissues translate into different roles for ARID3B in carcinomas. ARID3B (AT-rich interaction domain 3) is a member of the family of ARID proteins, which constitutes evolutionarily conserved transcription factors implicated in normal development, differentiation, cell cycle regulation and chromatin remodeling. In addition, ARID3B has been linked to cellular immortalization, epithelial-mesenchymal transition (EMT) and tumorigenesis. Given the emerging role of ARID3B in tumor development, we examined its expression in primary patient-derived breast cancer samples and breast cancer-derived cell lines. ARID3B regulation of direct target genes in the Wnt pathway promotes adhesion of ovarian cancer cells. ARID3A and ARID3B are transcriptional targets of p53, ARID3B play a key role in the expression of pro-apoptotic p53-target genes and apoptosis.
Immunogen: A synthetic peptide corresponding to the center region of the Human ARID3B
Buffer: 0.2 μm filtered solution in PBS
Dilution: WB 1:500-1:2000;
Calculated MW: 61 kDa
Observed MW: 68 kDa
English
Deutsch
